Literature DB >> 23686729

The perils of protection: vulnerability and women in clinical research.

Toby Schonfeld1.   

Abstract

Subpart B of 45 Code of Federal Regulations Part 46 (CFR) identifies the criteria according to which research involving pregnant women, human fetuses, and neonates can be conducted ethically in the United States. As such, pregnant women and fetuses fall into a category requiring "additional protections," often referred to as "vulnerable populations." The CFR does not define vulnerability, but merely gives examples of vulnerable groups by pointing to different categories of potential research subjects needing additional protections. In this paper, I assess critically the role of this categorization of pregnant women involved in research as "vulnerable," both as separate entities and in combination with the fetuses they carry. In particular, I do three things: (1) demonstrate that pregnant women qua pregnancy are either not "vulnerable" according to any meaningful definition of that term or that such vulnerability is irrelevant to her status as a research participant; (2) argue that while a fetus may be vulnerable in terms of dependency, this categorization does not equate to the vulnerability of the pregnant woman; and (3) suggest that any vulnerability that appends to women is precisely the result of federal regulations and dubious public perceptions about pregnant women. I conclude by demonstrating how this erroneous characterization of pregnant women as "vulnerable" and its associated protections have not only impeded vital research for pregnant women and their fetuses, but have also negatively affected the inclusion of all women in clinical research.

Entities:  

Mesh:

Year:  2013        PMID: 23686729     DOI: 10.1007/s11017-013-9258-0

Source DB:  PubMed          Journal:  Theor Med Bioeth        ISSN: 1386-7415


  50 in total

1.  Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs; notice.

Authors: 
Journal:  Fed Regist       Date:  1993-07-22

Review 2.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

Review 3.  Knowledge transfer and translation: examining how teratogen information is disseminated.

Authors:  Ilan Shahin; Adrienne Einarson
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-09-22

Review 4.  Informed consent in obstetric anesthesia.

Authors:  Brian M Broaddus; Shobana Chandrasekhar
Journal:  Anesth Analg       Date:  2011-04       Impact factor: 5.108

5.  The National Children's Study: a golden opportunity to advance the health of pregnant women.

Authors:  Anne Drapkin Lyerly; Margaret Olivia Little; Ruth R Faden
Journal:  Am J Public Health       Date:  2009-07-10       Impact factor: 9.308

6.  Mode of delivery: toward responsible inclusion of patient preferences.

Authors:  Margaret Olivia Little; Anne Drapkin Lyerly; Lisa M Mitchell; Elizabeth M Armstrong; Lisa H Harris; Rebecca Kukla; Miriam Kuppermann
Journal:  Obstet Gynecol       Date:  2008-10       Impact factor: 7.661

7.  Maternal depression and perception of teratogenicity.

Authors:  Asnat Walfisch
Journal:  J Popul Ther Clin Pharmacol       Date:  2012-10-11

8.  Informed consent--recall of risk information following epidural analgesia in labour.

Authors:  H D Swan; D C Borshoff
Journal:  Anaesth Intensive Care       Date:  1994-04       Impact factor: 1.669

9.  Bioethics, vulnerability, and protection.

Authors:  Ruth Macklin
Journal:  Bioethics       Date:  2003-10       Impact factor: 1.898

10.  Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population.

Authors:  Tubao Yang; Mark C Walker; Daniel Krewski; Qiuying Yang; Carl Nimrod; Peter Garner; William Fraser; Olufemi Olatunbosun; Shi Wu Wen
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-03       Impact factor: 2.890

View more
  5 in total

Review 1.  Ethics of studies of drugs in pregnancy.

Authors:  Doreen Matsui
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

2.  Women in HIV cure research: multilevel interventions to improve sex equity in recruitment.

Authors:  Mary E Grewe; Yuntong Ma; Adam Gilbertson; Stuart Rennie; Joseph D Tucker
Journal:  J Virus Erad       Date:  2016

3.  Ethical considerations in placebo-controlled randomised clinical trials.

Authors:  Kenneth R Kaufman
Journal:  BJPsych Open       Date:  2015-06-30

4.  Perspectives of Pregnant and Breastfeeding Women on Participating in Longitudinal Mother-Baby Studies Involving Electronic Health Records: Qualitative Study.

Authors:  Austen Hentschel; Chu J Hsiao; Lynn Y Chen; Lauren Wright; Jennifer Shaw; Xinsong Du; Elizabeth Flood-Grady; Christopher A Harle; Callie F Reeder; Magda Francois; Adetola Louis-Jacques; Elizabeth Shenkman; Janice L Krieger; Dominick J Lemas
Journal:  JMIR Pediatr Parent       Date:  2021-03-05

Review 5.  Pregnancy and COVID-19: pharmacologic considerations.

Authors:  R D'Souza; R Ashraf; H Rowe; J Zipursky; L Clarfield; C Maxwell; C Arzola; S Lapinsky; K Paquette; S Murthy; M P Cheng; I Malhamé
Journal:  Ultrasound Obstet Gynecol       Date:  2021-02       Impact factor: 8.678

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.